Yuchen Shen

Mr. Yuchen Shen


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
向向向岚岚 向
向岚岚 向
HWHao Wang
Hao Wang
JLJiajie Liu
Jiajie Liu
YSYuchen Shen
Yuchen Shen
YHYanFen Hu
YanFen Hu
Xin TengXin Teng
Xin Teng
Background/Objectives: Docetaxel is a potent anti-cancer agent capable of treating various types of cancer. However, it often induces a range of adverse reactions when used with its standard solubilizer, Tween-80, necessitating allergy prophylaxis with dexamethasone prior to administration. To mitigate the risk of allergic reactions, with nanomicelles garnering significant interest due to their enhanced solubility and thermodynamic stability. Methods: In this research, a mPEG-PLA-Lys(Fmoc) micellar carrier with m = 45 and n = 10 was engineered to encapsulate docetaxel, and its self-assembly into micelles was investigated. Additionally, allergic reaction studies were conducted on animals. Results: The findings indicated that the formulation did not cause hemolysis, vascular, or muscle irritation in rabbits, nor did it elicit an allergic response in guinea pigs. Conclusions: These results suggest that nanomicelle-encapsulated docetaxel can diminish the allergic reactions associated with docetaxel injections, offering a novel approach to enhance the therapeutic utility of this outstanding anti-cancer drug.

25 June 2026 in Molecules
Verified
Journal Article
Open access
PDF file
YXYukun Xie
Yukun Xie
HWHao Wang
Hao Wang
向向向岚岚 向
向岚岚 向
YSYuchen Shen
Yuchen Shen
YYYujie Yang
Yujie Yang
Xin TengXin Teng
Xin Teng
Taxanes represent a crucial class of chemotherapeutic agents clinically employed for the treatment of various malignancies, including breast cancer. Three commonly utilized taxanes—paclitaxel (Taxol), docetaxel (Taxotere), and cabazitaxel—are substantially limited by inherent drawbacks such as poor aqueous solubility, rapid clearance, and non-specific distribution. To enhance their anti-tumor efficacy against breast cancer, an mPEG-PLA-(LA)4 nanomicelle carrier was designed and synthesized in this study for the loading of these three taxanes. These nanomicelles were designed to improve the aqueous compatibility and nanomicelle-mediated delivery of hydrophobic taxanes. In vivo animal experiments were conducted to evaluate the therapeutic effects of the three drug-loaded nanomicelles on subcutaneous human breast cancer MCF-7 xenografts in BALB/c nude mice. The results demonstrated that the injectable paclitaxel, docetaxel, and cabazitaxel micelles exhibited significant inhibitory effects on the MCF-7 xenograft tumors. These findings suggest that mPEG-PLA-(LA)4 DS nanomicelles may serve as a structurally defined and versatile carrier platform for hydrophobic taxane delivery.